Safety and efficacy of interleukin-1 inhibitor anakinra for the amelioration of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem cell transplantation after high-dose melphalan.
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2018
At a glance
- Drugs Anakinra (Primary)
- Indications Fever; Mucositis
- Focus Adverse reactions
- Acronyms AFFECT-1
- 05 Dec 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Feb 2019.
- 31 Aug 2018 Biomarkers information updated
- 25 Oct 2017 Status changed from not yet recruiting to recruiting.